



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUN 12 2002
TECH CENTER 1600/2900

#14B
Dra
6/18/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Arnold J. Levine et al.

Application No.: 09/782,650

Filed: February 12, 2001

For: TARGETED ANGIOGENESIS

Examiner: Ram R. Shukla

Art Unit: 1632

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Communication mailed March 26, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 15-27 without prejudice or disclaimer.

REMARKS

Claims 1-7 and 15-29 are pending in the present application. The Examiner has requested that Applicants elect one group under 35 U.S.C. §121 as follows:

Group I encompasses claims 1-7 and 28-29. These claims are drawn to chimeric molecules comprising an angiogenic factor linked to targeting molecule, classified in class 530, subclass 350.

Group II encompasses claims 15-23, drawn to a method of increasing cardiac neovasculature, classified in class 514, subclass 2.